ArriVent BioPharma, Inc. Logo

ArriVent BioPharma, Inc.

A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.

AVBP | NDAQ

Overview

Corporate Details

ISIN(s):
US04272N1028
LEI:
Country:
United States of America
Address:
18 CAMPUS BLVD., NEWTOWN SQUARE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat diseases, with an initial focus on oncology. The company's strategy centers on forging strategic partnerships to in-license and accelerate the global development of promising drug candidates. Its pipeline is led by its lead development candidate, firmonertinib, an investigational cancer therapeutic, and includes other novel oncology treatments such as next-generation antibody-drug conjugates. ArriVent leverages its team's extensive drug development and regulatory expertise to advance its portfolio and address significant unmet medical needs for global patient populations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ArriVent BioPharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ArriVent BioPharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ArriVent BioPharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Develops & commercializes PET/CT tracers for diagnosing cancer & neurological disorders.
South Korea 176750
Dx & Vx Co., Ltd. Logo
Develops innovative diagnostics & vaccines and provides comprehensive life science contract services.
South Korea 180400
DYNAVAX TECHNOLOGIES CORP Logo
Biopharma firm developing novel vaccines, like its adult hepatitis B vaccine, with adjuvant tech.
United States of America DVAX
Dyne Therapeutics, Inc. Logo
Developing targeted therapies for genetic neuromuscular diseases via its FORCE™ platform.
United States of America DYN
Manufactures vet pharma for livestock/aquaculture & distributes premium pet food.
South Korea 044960
ECO ANIMAL HEALTH GROUP PLC Logo
Develops pharmaceuticals for respiratory & enteric diseases in global swine and poultry markets.
United Kingdom EAH
Ectin Research AB Logo
Clinical-stage biotech developing novel cancer treatments, focusing on metastatic bladder cancer.
Sweden ECTIN B
Edesa Biotech, Inc. Logo
Develops treatments for inflammatory and immune diseases like Acute Respiratory Distress Syndrome.
United States of America EDSA
Edgewise Therapeutics, Inc. Logo
Developing novel therapeutics for rare and serious muscle disorders.
United States of America EWTX
Editas Medicine, Inc. Logo
Developing CRISPR-based genomic medicines to treat serious and rare genetic diseases.
United States of America EDIT

Talk to a Data Expert

Have a question? We'll get back to you promptly.